
New tool can identify children who are likely to become obese in adulthood
It is hoped that the new resource will one day mean that those at highest risk will get targeted support to prevent them from becoming obese in the first place.
The tool, which assesses a person's genetic risk of obesity, works twice as well as any other obesity risk predictor, academics said.
As well as identifying children at risk of obesity, it can also predict how well obese adults will respond to targeted weight loss programmes.
Academics used detail on genetic variations from more than five million people to create a tool called a polygenic risk score, which analyses people's genetics to work out their risk of developing obesity.
The tool could explain 17.6% of variation in body mass index score (BMI) from people in the UK, they found.
Researchers, led by academics at the universities of Copenhagen and Bristol, tested whether the risk score was associated with obesity using datasets of the physical and genetic characteristics of more than 500,000 people.
This included checking the tool on people taking part in the 'Children of the 90s' study – a long-term study in Bristol tracking families as children age.
They found that it could successfully predict weight gain during childhood – from the age of just two and a half – through to adolescence.
'Overall, these data show that polygenic scores have the potential to improve obesity prediction, particularly when implemented early in life,' the authors wrote in the journal, Nature Medicine.
Lead author of the research, assistant professor Roelof Smit from the University of Copenhagen, said: 'What makes the score so powerful is the consistency of associations between the genetic score and body mass index before the age of five and through to adulthood – timing that starts well before other risk factors start to shape their weight later in childhood.
'Intervening at this point could theoretically make a huge impact.'
He told the PA news agency that BMI is not a good predictor for a child's obesity risk in later life but the genetic predictor can offer insight into the risk from early years.
#BetterHealth offers a range of free NHS apps to help people eat better and get active, including the NHS Weight Loss Plan app.
Data shows it can help people lose 5.8kg on average over just 12 weeks. Find out more: https://t.co/Bv6bumO9ZU pic.twitter.com/XQuL0z6unA
— NHS London (@NHSEnglandLDN) July 25, 2023
'Essentially it's fixed at conception already very early in life, you're able to essentially quantify what someone's innate predisposition is for BMI,' he said.
'So, being able to say something about someone's innate biology for obesity risk.'
Meanwhile, the research team also looked at people taking part in 'intensive lifestyle intervention' programmes.
People with a higher risk score lost more weight, but were also more likely to regain it.
Prof Smit added: 'There is a huge amount of variation in how people respond to these interventions.
'What we observed was the higher someone's score was, the more they tended to respond to the intervention – people who had a higher score tended to lose more weight in the first year.
'And we also saw that people who had the higher scores tended to gain more weight.'
Dr Kaitlin Wade, associate professor in epidemiology at the University of Bristol and second author on the paper, said: 'Obesity is a major public health issue, with many factors contributing to its development, including genetics, environment, lifestyle and behaviour.
'These factors likely vary across a person's life, and we believe that some of these originate in childhood.
'We were delighted to contribute data from the Children of the 90s study to this exceptional and insightful research into the genetic architecture of obesity.
'We hope this work will contribute to detecting individuals at high risk of developing obesity at an earlier age, which could have a vast clinical and public health impact in the future.'
In 2022, some 64% of adults in England were estimated to be overweight or living with obesity.
Last week, MPs on the Health and Social Care Committee launched a review into how the Government is tackling the nation's obesity epidemic.
It comes after ministers pledged to 'launch a moonshot to end the obesity epidemic' in the one-year plan to improve the health of the nation.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
a day ago
- The Independent
All the health conditions weight-loss drugs are being used and tested for
Blockbuster diabetes and weight loss drugs from Eli Lilly and Novo Nordisk - including Mounjaro, Zepbound, Ozempic and Wegovy - generated over U$40 billion in combined sales last year. However, Novo Nordisk has warned that the rise in copycat versions of its weight-loss drug in the U.S. and competition from Lilly across several markets is expected to hurt Wegovy sales this year. Both companies are actively exploring other medical uses for these GLP-1 drugs, aiming to broaden their market reach and secure wider health insurance coverage, a strategy that has already seen some success. Here are some of the other conditions the drugs are being used and tested for: Alcohol addiction A study conducted by the University of Copenhagen 's Psychiatric Centre Rigshospitalet, is investigating whether semaglutide - the main ingredient in Wegovy and Ozempic - can help reduce alcohol intake in 108 patients diagnosed with alcohol use disorder and obesity. Alzheimer's disease Novo Nordisk is testing semaglutide in a late-stage trial in patients with early Alzheimer's disease. The study, which will enrol 1,840 patients, could have an initial data readout as early as later this year. Cardiovascular disease Eli Lilly was testing tirzepatide - the main ingredient in Mounjaro and Zepbound - for patients with heart failure and obesity. Lilly had said it would enrol about 700 people in the study, but the company said in May that it had withdrawn its U.S. application for heart failure approval. The European Medicines Agency backed the use of Novo's semaglutide to help ease heart failure symptoms in people with obesity in September 2024. Chronic kidney disease Novo's Ozempic is approved in the United States for reducing the risk of kidney failure and disease progression, as well as the risk of death due to heart problems in diabetes patients with chronic kidney disease. Lilly's tirzepatide is being evaluated in a mid-stage study of patients with chronic kidney disease and obesity. Lilly plans to enrol up to 140 participants with the study expected to be completed next year. Liver disease Novo is testing semaglutide in a late-stage trial of patients with a common, but difficult to treat, type of fatty liver disease called non-alcoholic steatohepatitis, or NASH. The study is expected to be completed in April 2029 and include about 1,200 patients. Lilly's tirzepatide helped up to 74 per cent of patients achieve absence of the disease with no worsening of liver scarring at 52 weeks, compared with 13 per cent of patients on placebo, in a mid-stage trial for NASH, which is also now referred to as metabolic dysfunction-associated steatohepatitis, or MASH. Neurological disorders Researchers at the Danish Headache Centre are testing semaglutide along with a very low-calorie diet as a treatment for new-onset idiopathic intracranial hypertension, a condition associated with obesity in which blood pressure inside the head rises. The study has enrolled about 50 patients and is expected to be completed in October 2025. Sleep apnea Zepbound was approved by the U.S. Food and Drug Administration for obstructive sleep apnea in December 2024, making it the first drug to directly treat patients with the common disorder that causes breathing disruption while sleeping.


North Wales Chronicle
4 days ago
- North Wales Chronicle
Obesity to fuel rise in liver cancer cases
The proportion of cases of liver cancer linked to obesity are set to increase from 5% to 11%, a group of experts has said as they called for more to be done to tackle preventable cases from occurring in the first place. The number of new liver cancers around the world will rise from 0.87 million in 2022 to 1.52 million in 2050, according to projections published as part of a new Lancet Commission on Liver Cancer paper. Researchers said that the proportion of liver cancers caused by the most common cause of liver cancer – the hepatitis B virus – are set to reduce over the coming years. Cases caused by the hepatitis C virus are also expected to decline proportionately. But in contrast, liver cancer cases caused by alcohol and obesity are set to increase. Experts predicted that by 2050 some 21% of liver cancers will be caused by alcohol. And 11% will be caused by a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD) – formerly known as fatty liver disease, where fat builds up in a person's liver. The severe form of this condition is called metabolic dysfunction-associated steatohepatitis. The research team point out that 60% of liver cancers are preventable. They said that global deaths from liver cancer are expected to rise from 760,000 in 2022 to 1.37 million in 2050. 'These data suggest that preventive measures targeting a comprehensive number of risk factors for hepatocellular carcinoma are sorely needed,' the team of experts led by academics in Hong Kong wrote. The main treatment for MASLD is eating a balanced diet, being physically active and potentially losing weight. 'Liver cancer is a growing health issue around the world,' said Professor Jian Zhou, chairman of the Commission from Fudan University in China. #BetterHealth offers a range of free NHS apps to help people eat better and get active, including the NHS Weight Loss Plan app. Data shows it can help people lose 5.8kg on average over just 12 weeks. Find out more: — NHS London (@NHSEnglandLDN) July 25, 2023 'It is one of the most challenging cancers to treat, with five-year survival rates ranging from approximately 5% to 30%. 'We risk seeing close to a doubling of cases and deaths from liver cancer over the next quarter of a century without urgent action to reverse this trend.' First author, Professor Stephen Chan, from the Chinese University of Hong Kong, added: 'As three in five cases of liver cancer are linked to preventable risk factors, mostly viral hepatitis, alcohol and obesity, there is a huge opportunity for countries to target these risk factors, prevent cases of liver cancer and save lives.' Commenting on the study, Pamela Healy, chief executive of the British Liver Trust, said: 'Liver cancer is the fastest rising cause of cancer death in the UK, and just 13% of people diagnosed will survive for five years or more. 'We know that the biggest risk factors are having pre-existing liver cirrhosis or viral hepatitis, and this new analysis highlights that MASLD, also known as fatty liver disease, is expected to be linked to an increasing number of cases. 'As well as improving early detection through surveillance of people with cirrhosis, it is essential that we tackle these underlying causes and prioritise public health. 'By supporting people to maintain a healthy weight, cut down on alcohol and get tested and treated for hepatitis, we can prevent many cases of liver cancer and save lives.' In 2022, some 64% of adults in England were estimated to be overweight or living with obesity.

Western Telegraph
5 days ago
- Western Telegraph
Obesity to fuel rise in liver cancer cases
The proportion of cases of liver cancer linked to obesity are set to increase from 5% to 11%, a group of experts has said as they called for more to be done to tackle preventable cases from occurring in the first place. The number of new liver cancers around the world will rise from 0.87 million in 2022 to 1.52 million in 2050, according to projections published as part of a new Lancet Commission on Liver Cancer paper. Researchers said that the proportion of liver cancers caused by the most common cause of liver cancer – the hepatitis B virus – are set to reduce over the coming years. Cases caused by the hepatitis C virus are also expected to decline proportionately. But in contrast, liver cancer cases caused by alcohol and obesity are set to increase. Experts predicted that by 2050 some 21% of liver cancers will be caused by alcohol. And 11% will be caused by a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD) – formerly known as fatty liver disease, where fat builds up in a person's liver. The severe form of this condition is called metabolic dysfunction-associated steatohepatitis. The research team point out that 60% of liver cancers are preventable. They said that global deaths from liver cancer are expected to rise from 760,000 in 2022 to 1.37 million in 2050. 'These data suggest that preventive measures targeting a comprehensive number of risk factors for hepatocellular carcinoma are sorely needed,' the team of experts led by academics in Hong Kong wrote. The main treatment for MASLD is eating a balanced diet, being physically active and potentially losing weight. 'Liver cancer is a growing health issue around the world,' said Professor Jian Zhou, chairman of the Commission from Fudan University in China. #BetterHealth offers a range of free NHS apps to help people eat better and get active, including the NHS Weight Loss Plan app. Data shows it can help people lose 5.8kg on average over just 12 weeks. Find out more: — NHS London (@NHSEnglandLDN) July 25, 2023 'It is one of the most challenging cancers to treat, with five-year survival rates ranging from approximately 5% to 30%. 'We risk seeing close to a doubling of cases and deaths from liver cancer over the next quarter of a century without urgent action to reverse this trend.' First author, Professor Stephen Chan, from the Chinese University of Hong Kong, added: 'As three in five cases of liver cancer are linked to preventable risk factors, mostly viral hepatitis, alcohol and obesity, there is a huge opportunity for countries to target these risk factors, prevent cases of liver cancer and save lives.' Commenting on the study, Pamela Healy, chief executive of the British Liver Trust, said: 'Liver cancer is the fastest rising cause of cancer death in the UK, and just 13% of people diagnosed will survive for five years or more. 'We know that the biggest risk factors are having pre-existing liver cirrhosis or viral hepatitis, and this new analysis highlights that MASLD, also known as fatty liver disease, is expected to be linked to an increasing number of cases. 'As well as improving early detection through surveillance of people with cirrhosis, it is essential that we tackle these underlying causes and prioritise public health. 'By supporting people to maintain a healthy weight, cut down on alcohol and get tested and treated for hepatitis, we can prevent many cases of liver cancer and save lives.' In 2022, some 64% of adults in England were estimated to be overweight or living with obesity.